Dr. Reddy’s Laboratories Ltd. has announced the launch of Toripalimab, branded as Zytorvi®, in India, marking a significant milestone in oncology treatment. Approved by global regulators like the USFDA, EMA, and DCGI, Toripalimab is the first immuno-oncology drug for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). It offers a 48% reduction in the risk of disease progression or death when combined with standard chemotherapy.
This launch positions India as the third country globally, after China and the U.S., to access this next-generation PD-1 inhibitor. “Toripalimab is a revolutionary step in addressing the unmet needs of NPC patients in India, particularly in regions with high disease prevalence,” said M.V. Ramana, CEO of Branded Markets.
In Guwahati, a hub for advanced medical care in Northeast India, Toripalimab’s availability is expected to bolster the region’s oncology treatment capabilities. With nasopharyngeal carcinoma being prevalent in the northeastern states, this development provides a significant boost to Guwahati’s reputation as a center for cutting-edge healthcare services. This launch aligns with Dr. Reddy’s focus on expanding its innovative oncology portfolio while ensuring access to advanced treatments in emerging markets, meeting its goal of serving over 1.5 billion patients by 2030.
